Panbela Q4 net loss $6.5M; ASPIRE trial >50% enrolled; cash $2.6M

Panbela Therapeutics, Inc.

Net loss of $6.5M ($65.90/share) in Q4 2023 vs. $4.7M loss in Q4 2022.
Cash $2.6M at Dec 31, 2023; raised ~$9M in Jan 2024 registered offering.
ASPIRE Phase III trial for metastatic pancreatic cancer exceeds 50% enrollment; full enrollment (~600 patients) expected Q1 2025.
Research and development expense $6.1M in Q4, up from $3.5M year-over-year.
Divestiture of pediatric neuroblastoma program to US WorldMeds for up to $9.5M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Panbela Therapeutics, Inc. reported the quarter and full year ended December 31, 2023 results: net income Net loss in the fourth quarter of 2023 was $6.5 million, or $65.90 per diluted share, EPS $65.90 per diluted share.

Period: the quarter and full year ended December 31, 2023
Net income: Net loss in the fourth quarter of 2023 was $6.5 million, or $65.90 per diluted share
EPS: $65.90 per diluted share
Result: reported results

Exact text from the filing

Net loss in the fourth quarter of 2023 was $6.5 million, or $65.90 per diluted share, compared to a net loss of $4.7 million, or $344.61 per diluted share, in the fourth quarter of 2022.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001437749-24-009416

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.